SEARCH

SEARCH BY CITATION

References

  • Barnetson RStC, Pearson JMH & Rees RJW (1976) Evidence for prevention of borderline leprosy reactions by dapsone. Lancet ii 7996, 11711172.
  • Bernink EH & Voskens JE (1997) Study on the detection of leprosy reactions and the effect of prednisone on various nerves. Leprosy Review 68, 225232.
  • Bianconcini Trindade MA, Manini MIP, Masetti JH, Leite MA, Takahashi MDF & Naafs B (2005) Leprosy and HIV co-infection in five patients. Leprosy Review 76, 162166.
  • Browne SG (1984) Leprosy, 3rd edn. Acta Clinica Ciba-Geigy Ltd, Basle.
  • Bushby SRM (1964) Chemotherapy. In: Leprosy in Theory and Practice, 2nd edn (eds RGCochrane & TFDavey) John Wright and Sons Ltd, Bristol, pp. 344370.
  • Chaussinand R (1950) In: La Lèpre. Expansion Scientifique Française, Paris.
  • Cochrane RG (1964) Neuritis in leprosy. In: Leprosy in Theory and Practice, 2nd edn (eds RGCochrane and TFDavey) Wright, Bristol UK, pp. 410417.
  • Collen AFS, Kroon FP, Schippers EM, Naafs B & Lavrijsen APM (2005) Drie dermatologische uitingen van immune reconstitution disease (IRD). Nederlandsch Tijdschrift voor Dermatologie en Venereologie 15, 2225.
  • Croft RP, Nicholls PG, Richardus JH & Smith WC (2000) Incidence rates of acute nerve function impairment in leprosy prospective cohort analysis after 24 months (The Bangladesh Nerve Damage Study). Leprosy Review 71, 1833.
  • De Souza Araújo HC (1929) Febro leprotica. In: A lepra – estudos realisados em 40 paizes (1924–1927) Trabahos Do Instituto Oswaldo Cruz, Rio de Janeiro, pp. 179183.
  • Ekambaram V & Sithambaram M (1977) Selfhealing in non-lepromatous leprosy in the area of the ELEP Leprosy Control Project Dharmapuri (Tamil Nadu). Leprosy in India 49, 387392.
  • Girdhar BK, Girdhar A & Kumar A (2000) Relapses in multibacillary leprosy; effect of the length of treatment. Leprosy Review 71, 144153.
  • Goodwin CS (1968) The use of the voluntary muscle test in leprosy neuritis. Leprosy Review 39, 209216.
  • Hansen AH (1897) Facultative oder obligatorische Isolation der Leprösen. Report 1st Int. Lep. Conf. III, 110.
  • Jacobson RR & Hastings RC (1976) Rifampicin-resistant leprosy. Lancet 2, 13041305.
  • Jacobson RR & Krahenbuhl JL (1999) Leprosy. Lancet 353, 655660.
  • Katoch VM (1998) Is there a microbiological rationale for single dose treatment of leprosy? Leprosy Review 69, 25.
  • Kiran KU, Stanley JN & Pearson JMH (1985) The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid treatment regimen. Leprosy Review 56, 127134.
  • Kumar B, Dogra S & Kaur I (2004) Epidemiological characteristics of leprosy reactions: 15 years experience from north India. International Journal of Leprosy 72, 125133.
  • Lawn SD, Wood C & Lockwood DN (2003) Borderline tuberculoid leprosy; an immune reconstitution phenomenon in a human immunodeficiency virus infected person. Clinical Infectious Disease 36 (Suppl.), e5e6.
  • Li W, Ye G, Yang Z et al. (1990) Effect of 3 year multi-drug treatment in multi-bacillary leprosy patients. Proceedings of the Academy of Medical Science Peking Union Medical College 5, 3740.
  • Li H-Y (2000) Analysis of reversal reaction in leprosy patients following fixed duration MDT. Paper at the Asian Leprosy Congress in Agra, India.
  • Little D, Khanolkar-Young S, Coulthart A, Suneetha S & Lockwood D (2001) Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitiric oxide synthease expression in leprosy type I (reversal) reactions before and during prednisolone treatment. Infection and Immunity 69, 34133417.
  • Lockwood DN (1997) Rifampicine/minocycline and ofloxacin (ROM) for single lesions – what is the evidence. Leprosy Review 68, 299300.
  • Lockwood DNJ (2002) Leprosy elimination – a virtual phenomenon or a reality? British Medical Journal 324, 15161518.
  • Lockwood D & Bryceson A (2003) The return of thalidomide: new uses and renewed concerns – reply. Leprosy Review 74, 290294.
  • Lockwood DN & Scollard DM (1998) Report of workshop on nerve damage and reactions. International Journal of Leprosy 66, 498499.
  • Meima A (2004) The impact of leprosy control: epidemiological and modelling studies. Thesis, Erasmus University Medical Center, Rotterdam.
  • Moreira AL, Kaplan G, Villahermosa LG et al. (1998) Comparison of pentoxifylline, thalidomide and prednisolone in treatment of ENL. International Journal of Leprosy 66, 6165.
  • Naafs B (1981) Therapy of neuritis during reactions in leprosy. Health Cooperation Papers 2, 6570.
  • Naafs B (1988) The treatment of leprosy. In: Mycobacterial Disease: Developments in serodiagnosis and therapy (ed. DWMulder) Royal Tropical Institute, Amsterdam, Bulletin 313, pp. 5878.
  • Naafs B (1996) Treatment of reactions and nerve damage. International Journal of Leprosy 64, S21S28.
  • Naafs B (1998) Leprosy, no longer a public health problem after the year 2000. A political statement to be met. Memisa Medisch 64, 103106.
  • Naafs B (2000a) Viewpoint: leprosy after the year 2000. Tropical Medicine & International Health 5, 400403.
  • Naafs B (2000b) Current views on reactions in leprosy. Indian Journal of Leprosy 72, 97122.
  • Naafs B (2003a) The treatment duration of reversal reaction: a reappraisal. Back to the past. Leprosy Review 74, 386389.
  • Naafs B (2003b) The return of thalidomide: new uses and renewed concerns – reply. Leprosy Review 74, 294296.
  • Naafs B (2005) Letter to the editor. Leprosy Mailing List (noto@cefpas.it). January 2005.
  • Naafs B & Dagne T (1977) Sensory testing: a sensitive method in the follow-up of nerve involvement. International Journal of Leprosy 45, 364368.
  • Naafs B, Pearson JMH & Baar AJM (1976) A follow-up study of nerve lesions in leprosy during and after reaction using motor nerve conduction velocity. International Journal of Leprosy 44, 188197.
  • Naafs B, Pearson JMH & Wheate HW (1979) Reversal reaction: the prevention of permanent nerve damage. Comparison of short- and long-term steroid treatment. International Journal of Leprosy 47, 712.
  • Naafs B, Lyons NF, Madombi L, Matemera BO & Ellis BPB (1986) Short term WHO advised multi drug treatment of paucibacillary leprosy patients. Indian Journal of Leprosy 58, 348353.
  • Noordeen SK (1993) Epidemiology and control of leprosy, a review of progress over the last 30 years. Transactions Royal Society of Tropical Medicine and Hygiene 87, 515517.
  • Opromolla DVA (2000) O tratemento das reações na hanseniase. Treatment of the reactions in leprosy. Hansenologia Internationalis 25, 16.
  • Opromolla DVA, Tonello CJS & Fleury RN (2000) Borderline leprosy and HIV infection. Hansenologia Internationalis 25, 5459.
  • Otters JBM & Gieteling MJ (1995) A follow-up study of 21 outpatients treated with a short-term steroid regimen. Term paper, University of Rotterdam.
  • PAHO (2004) Bauru consensus for validating leprosy diagnosis in endemic states in Brasil. PAHO document, http://www.paho.org .
  • Pannikar V (2003) The return of thalidomide: new uses and renewed concerns. Leprosy Review 74, 286288.
  • Pearson JMH & Weddell G (1971) Changes in sensory acuity following radial nerve biopsy in patients with leprosy. Brain 94, 4350.
  • Pereira GFM (2003) On thalidomide and WHO policies. Leprosy Review 74, 288290.
  • Post E, Chin-A-Lien RAM, Bouman C, Naafs B & Faber WR (1994) Lepra in Nederland in de periode 1970–1991. Nederlandsch Tijdschrift voor Geneeskunde 138, 19601963.
  • Prabhavolkar AB & Ansari K (1997) Patterns of indoor admissions of leprosy patients in preMDT and postMDT era and a role for a leprosy referral hospital in a leprosy integration programme. Indian Journal of Leprosy 69, 159167.
  • Richardus JH, Withington SG, Anderson AM et al. (2003) Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Leprosy Review 74, 311318.
  • Rogers L & Muir E (1940) Prophylaxis. In: Leprosy, 2nd edn (eds LRogers & EMuir) John Wright and Sons Ltd, Bristol, pp. 98138.
  • Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC & Sarno EM (1998) Pentoxifylline decreases in vivo and in vitro tumor necrosis factor alpha (TNF-alpha) in lepromatous patients with Erythema Nodosum Leprosum (ENL). Clinical and Experimental Immunology 111, 300308.
  • Schreuder PA (1998) The occurrence of reactions and impairments in leprosy: experiences in the leprosy control program of three provinces in North-eastern Thailand (1978–1995). II. Reactions. International Journal of Leprosy 66, 159169.
  • Schreuder PA & Naafs B (2003) Chronic ENL, steroid dependent: long-term treatment with high dose clofazimine. Leprosy Review 74, 386389.
  • Shepard CC, Levy L & Fasal P (1969) The sensitivity for dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment. American Journal of Tropical Medicine and Hygiene 18, 258264.
  • Sheskin J & Sagher F (1968) Trials with thalidomide derivatives in leprosy reactions. Leprosy Review 39, 203205.
  • Tadesse A & Shannon EJ (2005) Concerns regarding in vitro and in vivo uses of thalidomide. Leprosy Review 76, 9496.
  • Thacker AK, Chandra S, Mukhija RD & Sarkari NB (1996) Electro-physiological evaluation of nerves during reactions in leprosy. Journal of Neurology 243, 530535.
  • Touw-Langendijk EM, Brandsma JW & Andersen JG (1984) Treatment of ulnar and median nerve function loss in borderline leprosy. Leprosy Review 55, 4146.
  • Van Brakel WH & Khawas IB (1994) Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal. Part 1. Definitions, methods and frequencies. Leprosy Review 65, 204221.
  • Visschedijk J, Van den Broek J, Eggens H, Lever P, Van Beers S & Klatser P (2000) Mycobacterium leprae – millennium resistant! A review of leprosy control on the threshold of a new era. Tropical Medicine & International Health 5, 388399.
  • Warndorff-Van Diepen T (1982) Clofazimine-resistant leprosy, a case report. International Journal of Leprosy 50, 139142.
  • Waters MF (1993) Chemotherapy of leprosy, current status and future prospects. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 500503.
  • Waters MF (1998) Is it safe to shorten multidrug therapy of lepromatous (LL and BL) leprosy to 12 month. Leprosy Review 69, 110111.
  • WHO (1982) Chemotherapy of leprosy for control programmes. Technical Report Series 675.
  • WHO (1985) Expert Committee on leprosy. Sixth report. Technical Report Series 768.
  • WHO (1994) Chemotherapy of leprosy. Technical Report Series 847.
  • WHO (1998) Expert Committee on leprosy. Technical Report series 874.
  • WHO (2000) Weekly epidemiological records 75, 226231.
  • WHO (2002a) The final push strategy to eliminate leprosy as a public health problem; questions and answers. WHO, Geneva.
  • WHO (2002b) Report on the third meeting of the WHO technical advisory group on elimination of leprosy. (WHO/CDS/CPE/CEE/2002.29) WHO, Geneva.
  • WHO (2005) Global strategy for further reducing the leprosy burden and sustaining leprosy control activities (plan period 2006–2010). (WHO/CDS/CEE/2005.53).